Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Preclinical data suggest bortezomib and rituximab have synergy for mantle cell lymphoma (MCL). The authors studied bortezomib, rituximab, and dexamethasone in relapsed and refractory MCL using 1.3 mg/m2 of bortezomib on days 1, 4, 8, and 11 with rituximab on day 1 and 40 mg of dexamethasone on days 1-4.

Bortezomib, Rituximab, and Dexamethasone for Relapsed Mantle Cell Lymphoma